Capricor Therapeutics Inc
CAPRHealthcare|Biotechnology|USA
$21.50
-0.99 (-4.40%)
Tangible Book
$4.83
Financials
Financial Snapshot
Market Cap
$1.25B
Enterprise Value
$263.8M
Revenue (TTM)
$0.00
Net Income (TTM)
$-114.6M
Cash & Equivalents
—
Net Cash/Share
$4.01
Free Cash Flow (TTM)
$-114.0M
Operating CF (TTM)
$-92.6M
Debt/Equity
0.05
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$23.2M
Monthly Burn
$7.7M
Est. Runway
—
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $16.2M | $14.1M | $7.3M | $9.9M | $32.7M | $34.9M | $41.4M | $39.5M | $151.5M | $318.1M | $278.6M | |
| Operating Cash Flow | $-14.5M | $-14.2M | $-13.9M | $-6.8M | $-10.1M | $-16.8M | $4.9M | $-25.6M | $-40.0M | $-69.8M | $-92.6M | |
| Free Cash Flow | $-14.6M | $-14.3M | $-14.2M | $-6.8M | $-10.6M | $-18.0M | $1.6M | $-27.6M | $-41.5M | $-81.5M | $-114.0M | |
| Capital Expenditure | $-194.0K | $-32.0K | $-316.0K | $0.00 | $-548.0K | $-1.2M | $-3.4M | $-2.0M | $-1.5M | $-11.7M | $-21.3M | |
| Financing Cash Flow | $18.6M | $11.6M | $6.9M | $9.2M | $33.4M | $20.2M | $4.9M | $25.6M | $152.8M | $248.9M | $250.3M |
R&D Spending
R&D (TTM)
$92.9M
R&D Intensity
—
R&D Growth YoY
+10.0%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.2M | $2.7M | $1.7M | $1.0M | $310.0K | $245.0K | $2.6M | $25.2M | $22.3M | $0.00 | $0.00 | |
| R&D Expense | $16.0M | $10.8M | $12.1M | $5.1M | $8.5M | $13.6M | $21.8M | $36.4M | $50.0M | $84.5M | $92.9M | |
| R&D % of Revenue | 502.9% | 403.8% | 722.1% | 511.6% | 2728.1% | 5539.2% | 855.2% | 144.8% | 224.4% | — | — | |
| SG&A | $4.9M | $4.8M | $4.9M | $3.6M | $5.5M | $7.6M | $10.3M | $12.4M | $14.2M | $22.7M | $26.0M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.2M | $2.7M | $1.7M | $1.0M | $310.0K | $245.0K | $2.6M | $25.2M | $22.3M | $0.00 | $0.00 | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $3.2M | $2.7M | $1.7M | $1.0M | $310.0K | $245.0K | $2.6M | $25.2M | $22.3M | $0.00 | $0.00 | |
| R&D | $16.0M | $10.8M | $12.1M | $5.1M | $8.5M | $13.6M | $21.8M | $36.4M | $50.0M | $84.5M | $92.9M | |
| SG&A | $4.9M | $4.8M | $4.9M | $3.6M | $5.5M | $7.6M | $10.3M | $12.4M | $14.2M | $22.7M | $26.0M | |
| Operating Income | $-17.0M | $-12.9M | $-15.3M | $-7.7M | $-13.7M | $-20.9M | $-29.7M | $-24.1M | $-42.6M | $-108.1M | $-119.9M | |
| Interest Expense | $-345.0K | $-399.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-3.0M | $0.00 | |
| Pretax Income | $-18.8M | $2.4M | $-15.2M | $-7.6M | $-13.7M | $-20.0M | $-29.0M | $-22.3M | $-40.5M | $-105.0M | $-114.6M | |
| Net Income | $-18.8M | $2.4M | $-15.2M | $-7.6M | $-13.7M | $-20.0M | $-29.0M | $-22.3M | $-40.5M | $-105.0M | $-114.6M | |
| EPS (Diluted) | -10.10 | 0.90 | -5.17 | -2.06 | -0.88 | -0.87 | -1.18 | -0.83 | -1.15 | -2.26 | -2.32 | |
| EBITDA | $-18.3M | $3.0M | $-15.2M | $-7.6M | $-13.5M | $-20.7M | $-29.2M | $-23.0M | $-39.0M | $-100.1M | $-111.8M | |
| Shares Out. (M) | 1.85 | 2.68 | 2.94 | 3.71 | 15.57 | 23.09 | 24.55 | 26.78 | 35.22 | 46.48 | 57.43 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.2M | $6.1M | $4.3M | $3.9M | $32.7M | $34.9M | $9.6M | $14.7M | $11.3M | $287.8M | $105.4M | |
| Marketable Securities | $13.0M | $8.0M | $3.0M | $6.0M | $0.00 | $0.00 | $31.8M | $24.8M | $140.2M | $30.3M | $173.2M | |
| Total Current Assets | $18.1M | $15.7M | $8.5M | $10.5M | $33.7M | $36.4M | $42.9M | $50.9M | $163.4M | $322.9M | $283.1M | |
| Total Assets | $18.7M | $16.3M | $9.2M | $11.1M | $34.6M | $41.3M | $50.1M | $58.7M | $170.5M | $355.9M | $326.3M | |
| Total Current Liabilities | $4.9M | $1.7M | $1.3M | $898.0K | $3.0M | $4.1M | $23.6M | $31.3M | $21.0M | $35.8M | $33.6M | |
| Long-Term Debt | $13.9M | $0.00 | $0.00 | $0.00 | $71.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $22.8M | $5.0M | $4.6M | $4.3M | $6.4M | $10.0M | $38.3M | $36.1M | $25.0M | $50.2M | $47.6M | |
| Stockholders' Equity | $-4.0M | $11.2M | $4.6M | $6.8M | $28.2M | $31.4M | $11.8M | $22.6M | $145.5M | $305.8M | $278.7M | |
| Retained Earnings | $-54.0M | $-51.5M | $-66.7M | $-74.4M | $-88.0M | $-108.1M | $-137.1M | $-159.4M | $-199.8M | $-304.9M | $-338.8M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-14.5M | $-14.2M | $-13.9M | $-6.8M | $-10.1M | $-16.8M | $4.9M | $-25.6M | $-40.0M | $-69.8M | $-92.6M | |
| Capital Expenditure | $-194.0K | $-32.0K | $-316.0K | $0.00 | $-548.0K | $-1.2M | $-3.4M | $-2.0M | $-1.5M | $-11.7M | $-21.3M | |
| Free Cash Flow | $-14.6M | $-14.3M | $-14.2M | $-6.8M | $-10.6M | $-18.0M | $1.6M | $-27.6M | $-41.5M | $-81.5M | $-114.0M | |
| Investing Cash Flow | $-5.2M | $5.0M | $4.7M | $-3.0M | $5.4M | $-1.2M | $-35.1M | $5.1M | $-116.2M | $97.5M | $-81.1M | |
| Financing Cash Flow | $18.6M | $11.6M | $6.9M | $9.2M | $33.4M | $20.2M | $4.9M | $25.6M | $152.8M | $248.9M | $250.3M | |
| Issuance of Stock | $13.9M | $11.1M | $6.7M | $9.2M | $27.3M | $20.2M | $4.8M | $25.5M | $152.3M | $237.0M | $237.0M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Issuance of Debt | $4.8M | $500.0K | $0.00 | $0.00 | $318.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Payments of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $2.0M | $1.7M | $1.7M | $701.0K | $2.0M | $3.0M | $4.5M | $7.4M | $9.8M | $17.2M | $17.4M | |
| Net Change in Cash | $-1.0M | $2.3M | $-2.3M | $-646.0K | $28.8M | $2.2M | $-25.3M | $5.1M | $-3.4M | $276.6M | $76.6M |
Dilution Tracker
Shares outstanding grew 148.8% over 5 years — significant dilution
Shares Outstanding
57M
5-Year Share Growth
+148.8%
Stock Issuance (TTM)
$237.0M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 1.85 | 2.68 | 2.94 | 3.71 | 15.57 | 23.09 | 24.55 | 26.78 | 35.22 | 46.48 | 57.43 | |
| YoY Change % | — | 44.4% | 9.8% | 26.2% | 319.6% | 48.3% | 6.3% | 9.1% | 31.5% | 32.0% | 23.6% | |
| Stock Issuance | $13.9M | $11.1M | $6.7M | $9.2M | $27.3M | $20.2M | $4.8M | $25.5M | $152.3M | $237.0M | $237.0M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $2.0M | $1.7M | $1.7M | $701.0K | $2.0M | $3.0M | $4.5M | $7.4M | $9.8M | $17.2M | $17.4M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin % | -532.2% | -482.4% | -917.2% | -769.6% | -4416.1% | -8546.1% | -1164.1% | -95.6% | -191.1% | 0.0% | - | |
| Net Margin % | -589.6% | 91.2% | -909.1% | -760.4% | -4405.5% | -8172.7% | -1137.6% | -88.5% | -181.7% | 0.0% | - | |
| EBITDA Margin % | -574.8% | 111.6% | -907.8% | -752.4% | -4369.7% | -8446.1% | -1143.2% | -91.4% | -175.3% | 0.0% | - | |
| FCF Margin % | -459.2% | -535.0% | -848.5% | -678.8% | -3420.3% | -7349.0% | 61.0% | -109.8% | -186.5% | 0.0% | 0.0% | |
| ROE % | 0.0% | 67.3% | -191.8% | -133.4% | -78.0% | -67.2% | -134.5% | -129.6% | -48.2% | -46.6% | -63.6% | |
| ROA % | -108.0% | 13.9% | -119.0% | -75.1% | -59.7% | -52.7% | -63.5% | -41.0% | -35.3% | -39.9% | -52.3% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / 103.08 / 356.67
Industry Med.27.51
P/S—
Historical2.41 / 19.23 / 671.11
Industry Med.9.49
P/B4.45
Historical0.82 / 4.13 / 1486.96
Industry Med.2.93
EV/EBITDA-8.78
Historical-18.45 / -2.81 / 43.63
Industry Med.13.02
EV/Revenue—
Historical-6.60 / 16.68 / 500.86
Industry Med.8.59
P/FCF—
Historical9.00 / 20.39 / 62.18
Industry Med.27.13
Intrinsic Value Models
Tangible Book
$4.83
Net Current Assets
$4.080
Net-Net Working Capital
$4.01
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | At Loss | 17.56 | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | |
| PS Ratio | 15.47 | 15.88 | 7.22 | 4.72 | 171.50 | 266.36 | 37.12 | 5.20 | 21.84 | - | 0.00 | |
| PB Ratio | 0.00 | 3.70 | 2.79 | 0.98 | 2.50 | 2.26 | 8.27 | 6.74 | 4.32 | 5.41 | 4.45 | |
| EV/EBITDA | -2.98 | 9.21 | -0.37 | 0.42 | -2.82 | -1.88 | -2.01 | -5.00 | -12.27 | -13.51 | -8.78 | |
| EV/Revenue | 17.13 | 10.27 | 3.36 | -3.18 | 123.33 | 158.56 | 22.96 | 4.57 | 21.51 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
—
Distress
Piotroski F-Score
3
Weak
Beneish M-Score
—
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $137.86M | $128.37M | $351.35M |
| Net Income | $-19.77M | $-46.84M | $144.08M |
| EPS | -0.10 | -0.94 | 2.11 |
| Book Value per Share | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow per Share | 0.00 | 0.00 | 0.00 |
| Operating CF | $0.00M | $0.00M | $0.00M |
Dividends
Revenue Segments
By Business
| Segment | 2024 |
|---|---|
| Development and commercialization of its therapeutic candidates | $22.3M |
| Single Segment | $22.3M |
By Geography
| Segment | 2024 |
|---|---|
| United States | $22.3M |